2006
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
Berry D, Cirrincione C, Henderson I, Citron M, Budman D, Goldstein L, Martino S, Perez E, Muss H, Norton L, Hudis C, Winer E. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. Obstetrical & Gynecological Survey 2006, 61: 584-585. DOI: 10.1097/01.ogx.0000234789.05150.7c.Peer-Reviewed Original ResearchER-negative patientsER-positive patientsER-positive tumorsER-negative tumorsNode-positive breast cancerER-negative womenEstrogen receptor statusBreast cancerOverall survivalER statusLymph node-positive breast cancerER-positive breast cancerModern intensive chemotherapyWeak prognostic factorER-positive diseaseLeukemia Group BDisease-free survivalER-negative diseaseOverall survival ratePatterns of riskAdjuvant chemotherapyChemotherapy trialsEndocrine treatmentIntensive chemotherapyRecurrent disease
1999
Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis.
Parmigiani G, Berry D, Winer E, Tebaldi C, Iglehart J, Prosnitz L. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. Journal Of Clinical Oncology 1999, 17: 1465-73. PMID: 10334532, DOI: 10.1200/jco.1999.17.5.1465.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionBenefits of ALNDLymph node dissectionQuality of lifeAdjuvant chemotherapyAdjuvant therapyNode dissectionBreast cancerLeukemia Group B StudyEarly-stage breast cancerRoutine useAxillary radiation therapyER-negative womenER-positive womenAdjuvant systemic therapySmall primary tumorsBreast-conserving therapyBreast cancer patientsEstrogen receptor statusNegative axillaOxford OverviewAdjuvant treatmentChemotherapy combinationsSurvival benefitSystemic therapy